Cardiology Research, ISSN 1923-2829 print, 1923-2837 online, Open Access
Article copyright, the authors; Journal compilation copyright, Cardiol Res and Elmer Press Inc
Journal website http://www.cardiologyres.org

Original Article

Volume 9, Number 6, December 2018, pages 370-377

Clinical Outcomes of World’s Thinnest (50 μmr) Strut Biodegradable Polymer Coated Everolimus-Eluting Coronary Stent System in Real-World Patients

Figures

Figure 1.
Figure 1. Evermine 50 EES thinnest (50 µm) strut platform.
Figure 2.
Figure 2. Flow dynamics based on strut thickness.
Figure 3.
Figure 3. Time-to-event curve by Kaplan-Meier method at 6-month follow-up.

Tables

Table 1. Baseline Demographic and Clinical Characteristics
 
CharacteristicPatients (n = 251)
CABG: coronary artery bypass grafting; CAD: coronary artery disease; LVEF: left ventricular ejection fraction; MI: myocardial infarction; NSTEMI: non-ST-segment elevation myocardial infarction; PCI: percutaneous coronary intervention; PTCA: percutaneous transluminal coronary angioplasty; STEMI: ST-segment elevation myocardial infarction; n: number of patients. Data are presented as mean ± SD or as number and percentage.
Patients’ demographics
  Age (mean ± SD), years58.20 ± 9.92
  Male, n (%)193 (76.9)
  BMI (mean ± SD), kg/m225.02 ± 3.37
Medical history, n (%)
  Diabetes mellitus122 (48.6)
  Hypertension114 (45.4)
  Smokers38 (15.1)
  Alcoholic29 (11.6)
  Dyslipidemia15 (6)
  Chronic obstructive pulmonary disease2 (0.8)
  History of stroke4 (1.6)
  History of CABG1 (0.4)
  History of MI/PCI15 (6)
  History of ischemic heart disease207 (82.5)
  History of angina209 (83.7)
  History of other illness5 (2)
  Family history of CAD28 (11.2)
Cardiac status, n (%)
  Stable angina2 (0.8)
  Unstable angina26 (10.4)
  STEMI121 (48.2)
  NSTEMI23 (9.2)
  Asymptomatic/silent ischemic79 (31.5)
Disease vessel, n (%)
  Single vessel124 (49.4)
  Double vessels88 (35.1)
  Triple vessels39 (15.5)
Systolic blood pressure, mean ± SD126.23 ± 17.97
Diastolic blood pressure, mean ± SD78.72 ± 7.74
LVEF %, mean ± SD50.89 ± 8.24

 

Table 2. Lesions Characteristics
 
CharacteristicPatients (n = 251)/lesions (n = 474)
DVD: double vessel diseases; LAD: left anterior descending coronary artery; LCx: left circumflex coronary artery; LM: left main; RCA: right coronary artery; n: number of patients. Data are presented as mean ± SD or as number and percentage.
Total number of lesions treated with Evermine 50 EES343
Lesion per patient1.89
Evermine 50 EES stent per patient1.37
Lesion location (CASS Code), n ( % )
  RCA107/343 (31.2)
  LAD173/343 (50.4)
  LCx58/343 (16.9)
  Ramus5/343 (1.5)
Average stent length, mean ± SD23.50±12.21
Average stent diameter, mean ± SD2.83±0.23
ACC/AHA lesion class, n (%)
  A108/343 (31.5)
  B1160/343 (46.6)
  B221/343 (6.1)
  C54/343 (15.7)
Stenosis type, n (%)
  De novo337/343 (98.2)
  In-stent3/343 (0.9)
  Bifurcation3/343 (0.9)

 

Table 3. Procedural Characteristics
 
Procedural characteristicsPatients (n = 251)
Index procedure characteristics, n (%)
  Pre-dilation262/343 (76.4)
  Post-dilation196/343 (57.1)
  Total occlusion45/343 (13.1)
TIMI flow pre procedure, n (%)
  038/343 (11.1)
  129/343 (8.5)
  235/343 (10.2)
  3241/343 (70.3)
TIMI flow post procedure, n (%)
  04/343 (1.2)
  10/343 (0.0)
  23/343 (0.9)
  3336/343 (98)
Medication at discharge, n (%)
  Aspirin251/251 (100.0)
  Ticagrelor225/251 (89.6)
  Clopidogrel17/251 (6.8)
  Prasugrel8/251 (3.2)
  Statins15/251 (6.0)

 

Table 4. Cumulative Clinical Outcomes at 6-Month Follow-up
 
EventsIn-hospital, n (%)1-month, n (%)6-month, n (%)
n = 251 (100%)n = 251 (100%)n = 251 (100%)
CD-TLR: clinically-driven target lesion revascularization; MACE: major adverse cardiac event; MI: Myocardial infarction; ST: stent thrombosis; n: number of patients.
All cause death0 (0.0)0 (0.0)2 (0.8%)
  Cardiac death0 (0.0)0 (0.0)1 (0.4%)
  Non-cardiac death0 (0.0)0 (0.0)1 (0.4%)
MI0 (0.0)0 (0.0)0 (0.0%)
CD-TLR0 (0.0)0 (0.0)1 (0.4%)
ST0 (0.0)0 (0.0)0 (0.0%)
MACE0 (0.0)0 (0.0)2 (0.8%)